Biovica International AB
Mattias Bergqvist is an experienced professional in the life sciences sector, currently serving as an Angel Investor at LSI Epsilon since January 2024 and holding multiple roles at Biovica International AB, including Clinical Development Director and former VP of Clinical Development since February 2017. As CEO of Life Science Solution Consulting AB since December 2012, Mattias has contributed significantly to various organizations, including serving as a Board Member at Scandinavian CRO from April 2020 to July 2024 and as Marketing Director at Biovica International AB from April 2012 to January 2015. Prior experience at AstraZeneca from January 2000 to April 2012 includes roles such as Therapy Area Director for Oncology and Global Brand Manager, enhancing expertise in clinical development and marketing strategies. Educational achievements include a BSc in Economy from the University of Borås and studies at Stockholm University.
This person is not in any teams
This person is not in any offices
Biovica International AB
Biovica develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and predict patient outcomes. The company’s DiviTum™ TKa assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality. Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum™ is CE-labeled and MPA-registered.